Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1246

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Locally Advanced Urothelial Cancer
Metastatic Urothelial Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Cisplatin + Gemcitabine
DRUG: Carboplatin + Gemcitabine

Sponsor

AstraZeneca